Biomarker for predicting adverse events in patients with acute pulmonary embolism and application thereof

A technology for adverse events and pulmonary embolism, applied in the field of medical biology, can solve the problems of lack of predictive indicators or predictive models for long-term outcomes

Pending Publication Date: 2020-02-21
BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Evaluation of clinical risk assessment models, biomarkers, echocardiography, and imaging can help clinicians identify high-risk patients. However, whether it is biomarkers or clinical prediction models, the current prognosis of acute pulmonary embolism is mainly based on short-term (30 days) Prognostic evaluation, lack of predictors or predictive models for long-term outcome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for predicting adverse events in patients with acute pulmonary embolism and application thereof
  • Biomarker for predicting adverse events in patients with acute pulmonary embolism and application thereof
  • Biomarker for predicting adverse events in patients with acute pulmonary embolism and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Elevated LCN-2 levels predict adverse long-term outcomes in hemodynamically stable patients with acute pulmonary embolism

[0048] A total of 170 hemodynamically stable patients with acute pulmonary embolism were selected, and the median follow-up time was 467 days (interquartile range: 288-715 days). According to the follow-up results, the patients were divided into event group and non-event group with long-term adverse outcomes The group conducted an ELISA experiment of plasma protein markers to verify whether LCN-2 can effectively predict the long-term adverse outcome of hemodynamically stable patients with acute pulmonary embolism by detecting the expression level of LCN-2. The long-term adverse event outcomes include but are not limited to: death, recurrence of thromboembolism.

[0049] 1. Experimental steps:

[0050] Reagent test kit: Human Lipocalin-2ELISA Kit

[0051] 1. Reagent preparation

[0052] 1.1 Experimental materials and reagents

[0053]...

Embodiment 2

[0087] Example 2: In patients with acute pulmonary embolism in the intermediate-risk group, plasma LCN-2 levels can improve the prediction model for risk stratification of adverse events

[0088] (1) The long-term adverse events of LCN-2 level ≥ 11 ng / ml in patients with acute pulmonary embolism in the intermediate-risk group are worse than those in the intermediate-risk group with LCN-2 < 11 ng / ml:

[0089] according to image 3 The cut-off value (cut-off value) can be determined to be 11ng / ml by calculating the Youden index from the ROC curve. Among the 126 patients in the intermediate-risk group, there are 43 patients with LCN-2≥11ng / ml, and 83 patients with LCN-2<11ng / ml .

[0090] The long-term MAEs outcomes of LCN-2 ≥ 11 ng / ml and LCN-2 Figure 5As shown by the Kaplan-Meier survival curve, the survival curve of patients with acute pulmonary embolism in the intermediate-risk group with LCN-2≥11ng / ml was significantly worse than that in the intermediate-risk group with LC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a biomarker for predicting adverse events in patients with the acute pulmonary embolism, an application thereof, and in particular, an application of lipocalin-2 (LCN-2) for predicting the long-term poor outcomes of the hemodynamically stable acute pulmonary embolism. The long-term poor outcomes refer to all-cause mortality and/or recurrent events of venous thromboembolism. The application relates to: the LCN-2 can independently predict the long-term poor prognosis of the hemodynamically stable acute pulmonary embolism, and meanwhile the risk re-stratification abilityof the long-term poor outcomes of intermediate-risk groups of patients with the acute pulmonary embolism can be improved based on the current risk stratification in combination with the LCN-2 (critical value 11ng/m1).

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and in particular relates to a biomarker for predicting adverse events in patients with acute pulmonary embolism and its application. Background technique [0002] Acute venous thromboembolism (VTE), including deep venous thromboembolism (DVT) and acute pulmonary embolism (PE), is one of the major causes of cardiovascular death and has clinical characteristics of high mortality and disability. The most clinically severe form of VTE, the prognosis of acute pulmonary embolism is typically heterogeneous. The vast majority of patients with acute pulmonary embolism are hemodynamically stable, accounting for about 95%. Patients with hemodynamically stable have a better prognosis, with an early mortality rate of 2%-15%. They may even be treated as outpatients depending on the situation . The long-term death of patients with acute pulmonary embolism is mainly affected by comorbid diseases, especial...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/53
CPCG01N33/6893G01N33/53G01N2800/122G01N2800/54
Inventor 杜杰李玉琳荆志成于海旭
Owner BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap